PMID- 23771664
OWN - NLM
STAT- MEDLINE
DCOM- 20140911
LR  - 20211021
IS  - 1672-0733 (Print)
IS  - 1672-0733 (Linking)
VI  - 33
IP  - 3
DP  - 2013 Jun
TI  - Accurate assessment of HER2 gene status for invasive component of breast cancer 
      by combination of immunohistochemistry and chromogenic In Situ hybridization.
PG  - 379-384
LID - 10.1007/s11596-013-1128-5 [doi]
AB  - The specimens of ductal carcinoma in situ (DCIS) with early invasion, and 
      specimens collected by core needle biopsy (CNB) tend to contain limited amount of 
      invasive component, so it is imperative to explore a new technique which can 
      assess HER2 gene status accurately for the limited invasive cancer component in 
      these specimens. Dual staining technique of combining immunohistochemistry (IHC) 
      for myoepithelial cells and single or dual probe chromogenic in situ 
      hybridization (CISH) for HER2 gene was performed on routinely processed paraffin 
      sections from 20 cases diagnosed as having DCIS with invasive cancer. Among them, 
      10 had fluorescence in situ hybridization (FISH)-confirmed amplification of HER2 
      and 10 had FISH-confirmed non-amplification of HER2. We successfully detected 
      HER2 genetic signals and myoepithelial IHC markers (SMM-HC or CK5/6) 
      simultaneously on a single section in all 20 specimens. Myoepithelial markers and 
      HER2 signals detected by dual staining assay were consistent with those by 
      individual technique performed alone. HER2 gene amplification results determined 
      by dual staining assay were 100% consistent with those of FISH. Dual staining 
      technique which allows simultaneous detection of myoepithelial marker protein and 
      cancerous HER2 gene is feasible, and it has potential to be used in clinical 
      practice for effective determination of HER2 amplification in limited invasive 
      component.
FAU - Nie, Xiu
AU  - Nie X
AD  - Department of Pathology, Huazhong University of Science and Technology, Wuhan, 
      430022, China.
FAU - He, Jun
AU  - He J
AD  - Department of Pathology, Huazhong University of Science and Technology, Wuhan, 
      430022, China.
FAU - Li, Yan
AU  - Li Y
AD  - Department of Pathology, Huazhong University of Science and Technology, Wuhan, 
      430022, China.
FAU - Pan, Dan-Zhen
AU  - Pan DZ
AD  - Department of Pathology, Huazhong University of Science and Technology, Wuhan, 
      430022, China.
FAU - Pan, Hua-Xiong
AU  - Pan HX
AD  - Department of Pathology, Huazhong University of Science and Technology, Wuhan, 
      430022, China.
FAU - Weng, Mi-Xia
AU  - Weng MX
AD  - Department of Pathology, Huazhong University of Science and Technology, Wuhan, 
      430022, China.
FAU - Yang, Xiu-Ping
AU  - Yang XP
AD  - Department of Pathology, Huazhong University of Science and Technology, Wuhan, 
      430022, China.
FAU - Liu, Chun-Ping
AU  - Liu CP
AD  - Department of Surgery, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, 430022, China.
FAU - Huang, Tao
AU  - Huang T
AD  - Department of Surgery, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, 430022, China. huangtaowh@163.com.
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130617
PL  - China
TA  - J Huazhong Univ Sci Technolog Med Sci
JT  - Journal of Huazhong University of Science and Technology. Medical sciences = Hua 
      zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. 
      Yixue Yingdewen ban
JID - 101169627
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Chromogenic Compounds)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Biomarkers, Tumor/*metabolism
MH  - Breast Neoplasms/genetics/*metabolism/*pathology
MH  - Chromogenic Compounds
MH  - Female
MH  - Gene Expression Profiling/methods
MH  - Humans
MH  - Immunohistochemistry/*methods
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Neoplasm Invasiveness/pathology/physiopathology
MH  - Receptor, ErbB-2/genetics/*metabolism
MH  - Reproducibility of Results
MH  - Sensitivity and Specificity
EDAT- 2013/06/19 06:00
MHDA- 2014/09/12 06:00
CRDT- 2013/06/18 06:00
PHST- 2013/01/22 00:00 [received]
PHST- 2013/06/18 06:00 [entrez]
PHST- 2013/06/19 06:00 [pubmed]
PHST- 2014/09/12 06:00 [medline]
AID - 10.1007/s11596-013-1128-5 [pii]
AID - 10.1007/s11596-013-1128-5 [doi]
PST - ppublish
SO  - J Huazhong Univ Sci Technolog Med Sci. 2013 Jun;33(3):379-384. doi: 
      10.1007/s11596-013-1128-5. Epub 2013 Jun 17.